An update from Chromocell Therapeutics Corp (CHRO) is now available.
Chromocell Therapeutics Corporation is set to present at the Sidoti Small Cap Conference, sharing updates on its product pipeline and recent business developments. Attendees will learn about the Company’s clinical trials for systemic chronic pain and eye pain treatments using its proprietary compound, CC8464. Additionally, the Company will discuss its sublingual and intranasal programs under an exclusive licensing agreement. Despite the forward-looking nature of these discussions, these statements are not guarantees of future performance and are subject to risks and uncertainties.
For a thorough assessment of CHRO stock, go to TipRanks’ Stock Analysis page.
